FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Leo Pharma Gets Updated Prescribing Info for Enstilar

[ Price : $8.95]

FDA approves a Leo Pharma supplemental NDA for updated prescribing information for Enstilar (calcipotriene and betamethasone dipro...

Regulatory Review Lags Yield Fewer Drugs in Development

[ Price : $8.95]

University researchers say delays in FDA new drug regulatory reviews lead to fewer new drugs being in development.

28 Drugs Not Withdrawn Due to Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that 28 drug products listed in the notice were not withdrawn from sale for safety or effe...

Complete Response Letter for Zosanos Qtrypta

[ Price : $8.95]

FDA issues a complete response letter for Zosano Pharmas Qtrypta 505(b)(2) NDA.

Guide on Postmarketing Requirements/Commitments

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Annual Status Report Information and Other Submissions for ...

Lilly Retains Outside Consultant to Help After Inspections

[ Price : $8.95]

Eli Lilly says it has retained an outside consultant to conduct a comprehensive independent review of systems at its Branchburg, N...

Fast Track Designation for TG Therapeutics Cancer Drug

[ Price : $8.95]

FDA grants fast track designation for TG Therapeutics ublituximab and umbralisib to treat chronic lymphocytic leukemia.

FDA Prevagen Concerns Aired

[ Price : $8.95]

A Wired investigation details how Quincy Bioscience has made millions from Prevagen sales despite many FDA questions and consumer ...

Tyber Medical Foot/Ankle Plating Systems Cleared

[ Price : $8.95]

FDA clears a Tyber Medical 501(k) for its new line of foot and ankle plating systems.

FDA Wants More Info on Helius Technologies PoNS

[ Price : $8.95]

FDA asks Helius Medical Technologies for more information to support its request for de novo clearance of its portable neuromodula...